Lafutidine Tablet 10 mg

Adult dosage

1. Short-term treatment of gastric ulcers: The usual dose of lafutidine is 10mg orally twice daily, in the morning and before bedtime. In clinical trials of up to 8 weeks, most ulcers healed within 8 weeks, although healing time may occasionally vary among patients. 2. Short-term treatment of duodenal ulcers: The usual dose of lafutidine is 10mg orally twice daily, in the morning and before bedtime. In clinical trials of up to 6 weeks, most ulcers healed within 6 weeks, although healing time may occasionally vary among patients. 3. Improvement of gastric mucosal lesions in acute and chronic gastritis: The usual dose of lafutidine is 10mg orally once daily before bedtime. In clinical trials of up to 2 weeks, most lesions healed within 2 weeks, although healing time may occasionally vary among patients. 4. Combination therapy with antibiotics for patients with peptic ulcers infected with Helicobacter pylori: Administer lafutidine 20mg, clarithromycin 500mg, and amoxicillin 1000mg twice daily for 7 or 14 days. 5. Premedication for anesthesia: The usual dose of lafutidine is 10mg per dose, administered orally twice (before bedtime on the day before surgery and 2 hours before anesthesia on the day of surgery). 6. Treatment of reflux esophagitis: Administer lafutidine 10mg per dose orally twice daily.

This medication should not be administered to patients with a hypersensitivity to its ingredients. This medication contains lactose, so patients with a genetic disorder that prevents the digestion of lactose should not use it. Patients who are allergic or hypersensitive to soybean oil, soy, or peanuts should also avoid taking this medication. Caution should be exercised in patients with a history of drug hypersensitivity, liver or kidney dysfunction, those undergoing dialysis, elderly patients, and patients with abnormalities in lipid metabolism. This medication can cause severe shock or anaphylactic reactions; if symptoms such as facial pallor, low blood pressure, or difficulty breathing occur during administration, the administration should be stopped immediately and proper treatment sought. Liver function impairment or symptoms of jaundice may occur, thus liver function tests should be conducted to monitor the condition and consumption of the medication should be stopped if abnormalities are found. Serious blood abnormalities such as agranulocytosis with decreased white blood cells or platelets may occur; if symptoms appear, the use of the medication should be stopped and treatment should be received. Rarely, serious side effects such as skin rash, seizures, and cardiac rhythm disturbances have been reported; if any unusual symptoms occur, prompt consultation with a medical professional is required. When taking this medication, various side effects such as constipation, diarrhea, nausea, headache, insomnia, drowsiness, dizziness, facial flushing, increased white blood cell count, elevated eosinophils, decreased white blood cell count, decreased red blood cell count, decreased hematocrit, elevated ALT (GPT), elevated AST (GOT), elevated Al-P, elevated γ-GTP, elevated T-Bil, elevated LDH, elevated TTT, and abnormal urine protein may occur, so caution is advised. Particularly, gastrointestinal symptoms or elevated liver enzymes have been reported, so if symptoms are severe or prolonged, consultation with a physician is necessary. This medication may mask the symptoms of malignant tumors; if symptoms such as weight loss, recurrent vomiting, or hematemesis are suspected, necessary tests should be conducted. If malignant gastric cancer is suspected or confirmed, this medication’s use must be suspended. During treatment, the course of the disease should be monitored closely, and if there is no effect, it is advisable to switch to another treatment method. Patients with lipid metabolism issues should monitor blood lipid levels, and adjust the dosage if necessary. Elderly patients may have decreased physical function; therefore, the dosage and intervals should be adjusted, and patient conditions should be closely observed. Patients undergoing dialysis may experience elevated drug concentrations in the blood, so treatment should begin with a low dose and be administered carefully. Pregnant women or women who could become pregnant should only take this medication if the benefits outweigh the risks as determined by a physician, and breastfeeding women should avoid taking this medication due to potential excretion in breast milk. Safety in pediatric patients has not been established, so caution is needed in use. Keep this medication out of reach of children and do not store the medication outside of its original container.

• Shock
• symptoms of anaphylaxis
• facial pallor
• hypotension
• generalized rash
• dyspnea
• liver function impairment
• jaundice
• agranulocytosis
• pharyngodynia

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Furthermore, it should be stored at room temperature between 1°C and 30°C. It is best to avoid excessively hot or cold places.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle